Arch Biopartners Inc - Asset Resilience Ratio

Latest as of September 2023: 69.72%

Arch Biopartners Inc (ARCH) has an Asset Resilience Ratio of 69.72% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CA$816.53K

≈ $590.67K USD Cash + Short-term Investments

Total Assets

CA$1.17 Million

≈ $847.21K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (1999–2023)

This chart shows how Arch Biopartners Inc's Asset Resilience Ratio has changed over time. See ARCH financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Arch Biopartners Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ARCH market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$816.53K	69.72%
Total Liquid Assets	CA$816.53K	69.72%

Asset Resilience Insights

Very High Liquidity: Arch Biopartners Inc maintains exceptional liquid asset reserves at 69.72% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Arch Biopartners Inc Industry Peers by Asset Resilience Ratio

Compare Arch Biopartners Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Abivax SA PA:ABVX	Biotechnology	2.34%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
INVENTIVA ADS/1 O.N. F:6IVA	Biotechnology	52.73%
Medincell SA PA:MEDCL	Biotechnology	45.63%
Alpha Tau Medical Ltd NASDAQ:DRTS	Biotechnology	65.79%

Annual Asset Resilience Ratio for Arch Biopartners Inc (1999–2023)

The table below shows the annual Asset Resilience Ratio data for Arch Biopartners Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-09-30	69.72%	CA$816.53K ≈ $590.67K	CA$1.17 Million ≈ $847.21K	+69.19pp
2000-09-30	0.52%	CA$12.40K ≈ $8.97K	CA$2.37 Million ≈ $1.71 Million	-3.03pp
1999-09-30	3.56%	CA$44.97K ≈ $32.53K	CA$1.26 Million ≈ $914.95K	--

pp = percentage points

About Arch Biopartners Inc

V:ARCH Canada Biotechnology

Market Cap

$43.24 Million

CA$59.78 Million CAD

Market Cap Rank

#23770 Global

#878 in Canada

Share Price

CA$0.88

Change (1 day)

+3.53%

52-Week Range

CA$0.41 - CA$1.75

All Time High

CA$5.00